At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 129 enrolled
Drug / intervention
Fruquintinib (HMPL-013)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Fruquintinib (HMPL-013) for Advanced Solid Tumors and 6 related conditions. Completed, enrolled 129 participants across 9 sites.
Detailed Summary
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Metastatic Colon Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Rectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartDec 2017
Primary CompletionDec 2022
Study CompletionMar 2023
TodayJul 2026
First PostedAug 16, 2017
Enrollment StartDec 11, 2017
Primary CompletionDec 13, 2022
Study CompletionMar 30, 2023
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.9 years ago
Interventions
Fruquintinib (HMPL-013)drug
Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.